Fairvalue-Calculator Fairvalue-Calculator
EN DE

Lukas Biomedical Inc (6814) Fair Value & Analysis

Healthcare · TW · Market cap 1.1B TWD

Price23.60 TWD
Fair Value17.21 TWD
Upside-27.1%
Quality95/100
Evidence: Low Range 12.91 TWD – 21.51 TWD

Fair value as of: Jun 24, 2026

Analysis

Lukas Biomedical Inc (6814) currently trades at 23.60 TWD, while our model-based Fair Value estimate is 17.21 TWD — implying the stock looks roughly 27.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases building equipment. In addition, the company involved in the new immune cell research and development, new product development, clinical trials, and production of cell reagents; and provision of brand management and medical management services. Lukas Biomedical Inc. was founded in 2002 and is based in New Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Lukas Biomedical Inc (6814) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 17.21 TWD versus a price of 23.60 TWD — about −27% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6814?
Our 21-model fair value for Lukas Biomedical Inc is 17.21 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 23.60 TWD.
What is the quality score of 6814?
Lukas Biomedical Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.